A comparison of six health systems — the United Kingdom, France, Germany, the United States, Australia, and Japan — reveals a consistent pattern: Despite radically different healthcare models, all exclude sleep disorders from chronic disease frameworks. OSA is managed episodically through device provision rather than long-term care pathways. The consistency of this pattern across systems suggests a structural design issue rather than a local policy failure, and points toward the need for OSA reclassification as a chronic condition requiring continuous management.
Sleep disorders are among the most prevalent medical conditions globally; obstructive sleep apnea (OSA) alone affects nearly 1 billion adults yet remains structurally invisible within most health systems. Across six countries, a consistent pattern emerges: Despite strong clinical evidence linking OSA and other sleep disorders to cardiovascular disease, diabetes, and premature mortality, sleep health remains peripheral to chronic disease frameworks, prevention strategies, and long-term care pathways. This is not a gap in the evidence. It is a gap in policy recognition.
Obstructive sleep apnea (OSA) is biologically heterogeneous, and distinct phenotypes show different treatment responses and adherence patterns. The current uniform, AHI‑driven care is misaligned with how the disease actually presents in many patients.
What happens when a therapy meets every regulatory requirement, but still isn’t covered? In sleep medicine, this is no longer an exception. It is a pattern. Devices can be FDA-cleared, clinically validated and fully coded, yet remain out of reach for patients due to fragmented and inconsistent payer policies.
